{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:26:26Z","timestamp":1789205186452,"version":"build-2803163510"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The WHO classification provides the best diagnostic approach to myelodysplastic syndromes (MDS). However, biologic and analytic limitations have emerged in the criteria currently adopted to establish the diagnosis and to classify MDS. The provisional category of idiopathic cytopenia of undetermined significance (ICUS) has been proposed to describe patients in whom MDS is possible but not proven. To formulate a diagnosis of ICUS, a thorough diagnostic work-up is required and repeated tests should be performed to reach a conclusive diagnosis. Recent studies provided consistent evidence of age-related hematopoietic clones (clonal hematopoiesis of indeterminate potential; CHIP), driven by mutations of genes that are recurrently mutated in myeloid neoplasms and associated with increase in the risk of hematologic cancer. A subset of mutated genes, mainly involved in epigenetic regulation, are likely initiating lesions driving the expansion of a premalignant clone. However, in a fraction of subjects the detected clone may be a small malignant clone expanding under the drive of the detected and additional undetected mutations. In addition, several experimental evidences suggest the potential relevance of an abnormal bone marrow environment in the selection and evolution of hematopoietic clones in MDS. The spreading of massively parallel sequencing techniques is offering translational opportunities in the clinical approach to myeloid neoplasms. Although several issues remain to be clarified, targeted gene sequencing may be of potential value in the dissection between clonal myelodysplasia, nonclonal cytopenia, and clonal hematopoiesis arising upon aging or in the context of acquired marrow failure.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.299","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"299-307","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)"],"prefix":"10.1182","volume":"2015","author":[{"given":"Luca","family":"Malcovati","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia Medical School, and"},{"name":"Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia Medical School, and"},{"name":"Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111705021729100_B1","first-page":"89","article-title":"Myelodysplastic Syndromes\/Neoplasms","volume-title":"WHO Classification of Tumors Of Haematopoietic and Lymphoid Tissues","author":"Brunning","year":"2008"},{"key":"2019111705021729100_B2","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","article-title":"The genetic basis of myelodysplasia and its clinical relevance","volume":"122","author":"Cazzola","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111705021729100_B3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"22","key":"2019111705021729100_B4","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111705021729100_B5","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2019111705021729100_B6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2013","journal-title":"Leukemia"},{"issue":"17","key":"2019111705021729100_B7","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111705021729100_B8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3324\/haematol.2011.056879","article-title":"Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors","volume":"97","author":"Parmentier","year":"2012","journal-title":"Haematologica"},{"key":"2019111705021729100_B9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2012.071449","article-title":"Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes","volume":"98","author":"Senent","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"2019111705021729100_B10","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3324\/haematol.13405","article-title":"Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts","volume":"93","author":"Mufti","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"2019111705021729100_B11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"2019111705021729100_B12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","article-title":"Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"issue":"17","key":"2019111705021729100_B13","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2011-03-342642","article-title":"Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers","volume":"118","author":"Naqvi","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111705021729100_B14","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.leukres.2007.03.015","article-title":"Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface","volume":"31","author":"Wimazal","year":"2007","journal-title":"Leuk Res"},{"issue":"11","key":"2019111705021729100_B15","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1093\/annonc\/mdq233","article-title":"Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients","volume":"21","author":"Schroeder","year":"2010","journal-title":"Ann Oncol"},{"key":"2019111705021729100_B16","doi-asserted-by":"crossref","first-page":"P092","DOI":"10.1016\/S0145-2126(09)70169-9","article-title":"Is idiopathic cytopenia of undetermined significance (ICUS) a valid clinical concept? A longitudinal clinicopathological study","volume":"33","author":"Hanson","year":"2009","journal-title":"Leukemia Res"},{"key":"2019111705021729100_B17","first-page":"261730","article-title":"Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European leukemianet working group","author":"Westers","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2019111705021729100_B18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood.V98.4.979","article-title":"Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome","volume":"98","author":"Stetler-Stevenson","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111705021729100_B19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2002-09-2768","article-title":"Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation","volume":"102","author":"Wells","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019111705021729100_B20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/sj.leu.2403680","article-title":"Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome","volume":"19","author":"Malcovati","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"2019111705021729100_B21","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2005-12-4916","article-title":"Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes","volume":"108","author":"Ogata","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111705021729100_B22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2012.066787","article-title":"Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics","volume":"98","author":"Kern","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"2019111705021729100_B23","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2019111705021729100_B24","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111705021729100_B25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2012-09-399725","article-title":"Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms","volume":"121","author":"Cazzola","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2019111705021729100_B26","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111705021729100_B27","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood.V83.10.2899.2899","article-title":"Tissue specificity of X-chromosome inactivation patterns","volume":"83","author":"Gale","year":"1994","journal-title":"Blood"},{"issue":"11","key":"2019111705021729100_B28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"2019111705021729100_B29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"26","key":"2019111705021729100_B30","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111705021729100_B31","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111705021729100_B32","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep"},{"issue":"1","key":"2019111705021729100_B33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111705021729100_B34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.13755","article-title":"Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach","volume":"94","author":"Bennett","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"2019111705021729100_B35","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"issue":"17","key":"2019111705021729100_B36","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","article-title":"Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome","volume":"124","author":"Kulasekararaj","year":"2014","journal-title":"Blood"},{"key":"2019111705021729100_B37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.V124.21.253.253","article-title":"Chronological analysis of clonal evolution in acquired aplastic anemia","volume":"124","author":"Yoshizato","year":"2014","journal-title":"Blood"},{"issue":"7488","key":"2019111705021729100_B38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"7290","key":"2019111705021729100_B39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature08851","article-title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia","volume":"464","author":"Raaijmakers","year":"2010","journal-title":"Nature"},{"issue":"21","key":"2019111705021729100_B40","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.V124.21.828.828","article-title":"Mutant splicing factor 3b subunit 1 (SF3B1) causes dysregulated erythropoiesis and a stem cell disadvantage","volume":"124","author":"Obeng","year":"2014","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/299\/1250871\/bep00115000299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/299\/1250871\/bep00115000299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T01:51:37Z","timestamp":1601085097000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/299\/20725\/The-shadowlands-of-MDS-idiopathic-cytopenias-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.299","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}